Text Size

Information, support and friendship

  • AMEND Information, support and friendship
  • AMEND Information, support and friendship
  • AMEND Information, support and friendship
  • AMEND Information, support and friendship
  • AMEND Information, support and friendship
  • AMEND Information, support and friendship
  • AMEND Information, support and friendship

AMEND, AMEND USA, AMEND Australia and AMEND New Zealand are all run by patients, for patients, to inform and support anyone affected by Multiple Endocrine Neoplasia (MEN) types 1, 2 and 3 and associated endocrine syndromes and tumours.

We are here to break the isolation so often felt by those with these rare diseases, and we would be delighted to welcome you into our 'family'.

The aim of our website is to direct you as quickly as possible to our support services and to information you can trust on MEN1, MEN2, MEN3, MTC (medullary thyroid cancer), FMTC (familial medullary thyroid cancer), adrenal gland tumours (phaeochromocytomas), parathyroid hyperplasia, paragangliomas, FIPA (familial isolated pituitary adenoma) and SDHx (succinate dehydrogenase) disorders.

 

MEN patient perspective films

 

spacer

 

 

AMEND 2015 Research Fund

AMEND's total Research Award Fund for 2015 is £50,000.

£40,000 of this is specifically for research projects directed to the study of medullary thyroid cancer (MTC).

The remaining £10,000 makes up our usual annual award for studies into endocrine tumours within the context of multiple endocrine neoplasia (MEN).

The AMEND Research Fund is now open and inviting good quality applications.

Click here for more information and to apply for an award.

 

Cabozantinib approved in Wales

In October 2014 AMEND made a submission on behalf of patients to the All Wales Therapeutics & Toxicology Centre in support of the appraisal for use of cabozantinib (Cometriq™) for metastatic medullary thyroid cancer (MTC).

We are pleased to report that the AWTTC confirmed on Tuesday 10th February, that the appraisal received Ministerial approval at the end of January 2015, and that cabozantinib will be available for use in patients with metastatic MTC by the end of April 2015.

Appraisal Lead, Dr Claire Davis expressed her thanks to AMEND for the submission: "I would like to thank you directly for your help with obtaining patient/carer views for the cabozantinib (Cometriq®) appraisal.  The information provided really helped to inform members of the appraisal groups."

   

Page 1 of 17

Polls

Your Top Medical Specialist Attribute

Donate via Paypal

AMEND donate

Make a donation using Virgin Money Giving

Coming Soon

 

AMEND search

AMEND Login

AMEND forum latest

More Topics »

Follow us on

  • Facebook Page: https://www.facebook.com/#!/pages/Association-for-Multiple-Endocrine-Neoplasia-Disorders-AMEND/151203075059428
  • Twitter: @AmendInfo
  • YouTube: AMEND3